TISIDB

Summary
Symbol	GPIHBP1
Name	glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1
Aliases	LOC338328; GPI-HBP1; endothelial cell LPL transporter; GPI anchored high density lipoprotein binding protein ......
Chromosomal Location	8q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Apical cell membrane Lipid-anchor, GPI-anchor Basolateral cell membrane Lipid-anchor, GPI-anchor Cell membrane Peripheral membrane protein Extracellular side
Domain	PF00021 u-PAR/Ly-6 domain
Function	Plays a key role in the lipolytic processing of chylomicrons. Required for the transport of lipoprotein lipase LPL into the capillary lumen (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0006869 lipid transport GO:0010876 lipid localization GO:0010984 regulation of lipoprotein particle clearance GO:0010986 positive regulation of lipoprotein particle clearance GO:0017038 protein import GO:0031647 regulation of protein stability GO:0034381 plasma lipoprotein particle clearance GO:0034382 chylomicron remnant clearance GO:0034394 protein localization to cell surface GO:0042632 cholesterol homeostasis GO:0045056 transcytosis GO:0050821 protein stabilization GO:0051004 regulation of lipoprotein lipase activity GO:0051006 positive regulation of lipoprotein lipase activity GO:0055088 lipid homeostasis GO:0055090 acylglycerol homeostasis GO:0055092 sterol homeostasis GO:0060191 regulation of lipase activity GO:0060193 positive regulation of lipase activity GO:0061365 positive regulation of triglyceride lipase activity GO:0070328 triglyceride homeostasis GO:0071503 response to heparin GO:0071806 protein transmembrane transport GO:0071830 triglyceride-rich lipoprotein particle clearance GO:0090320 regulation of chylomicron remnant clearance GO:0090321 positive regulation of chylomicron remnant clearance GO:0097006 regulation of plasma lipoprotein particle levels
Molecular Function	GO:0008035 high-density lipoprotein particle binding GO:0008320 protein transmembrane transporter activity GO:0008565 protein transporter activity GO:0022884 macromolecule transmembrane transporter activity GO:0035473 lipase binding GO:0035478 chylomicron binding GO:0071813 lipoprotein particle binding GO:0071814 protein-lipid complex binding
Cellular Component	GO:0009897 external side of plasma membrane GO:0016323 basolateral plasma membrane GO:0016324 apical plasma membrane GO:0031225 anchored component of membrane GO:0031233 intrinsic component of external side of plasma membrane GO:0031362 anchored component of external side of plasma membrane GO:0032994 protein-lipid complex GO:0034358 plasma lipoprotein particle GO:0034364 high-density lipoprotein particle GO:0045177 apical part of cell GO:0046658 anchored component of plasma membrane GO:0098552 side of membrane GO:1990777 lipoprotein particle

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-174800: Chylomicron-mediated lipid transport R-HSA-73923: Lipid digestion, mobilization, and transport R-HSA-174824: Lipoprotein metabolism R-HSA-1430728: Metabolism R-HSA-6806667: Metabolism of fat-soluble vitamins R-HSA-556833: Metabolism of lipids and lipoproteins R-HSA-392499: Metabolism of proteins R-HSA-196854: Metabolism of vitamins and cofactors R-HSA-163125: Post-translational modification R-HSA-597592: Post-translational protein modification R-HSA-975634: Retinoid metabolism and transport R-HSA-162582: Signal Transduction R-HSA-2187338: Visual phototransduction

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-174800: Chylomicron-mediated lipid transport
R-HSA-73923: Lipid digestion, mobilization, and transport
R-HSA-174824: Lipoprotein metabolism
R-HSA-1430728: Metabolism
R-HSA-6806667: Metabolism of fat-soluble vitamins
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-392499: Metabolism of proteins
R-HSA-196854: Metabolism of vitamins and cofactors
R-HSA-163125: Post-translational modification
R-HSA-597592: Post-translational protein modification
R-HSA-975634: Retinoid metabolism and transport
R-HSA-162582: Signal Transduction
R-HSA-2187338: Visual phototransduction

Summary
Symbol	GPIHBP1
Name	glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1
Aliases	LOC338328; GPI-HBP1; endothelial cell LPL transporter; GPI anchored high density lipoprotein binding protein ......
Chromosomal Location	8q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between GPIHBP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	GPIHBP1
Name	glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1
Aliases	LOC338328; GPI-HBP1; endothelial cell LPL transporter; GPI anchored high density lipoprotein binding protein ......
Chromosomal Location	8q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of GPIHBP1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	GPIHBP1
Name	glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1
Aliases	LOC338328; GPI-HBP1; endothelial cell LPL transporter; GPI anchored high density lipoprotein binding protein ......
Chromosomal Location	8q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of GPIHBP1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.543	0.117
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.441	0.485
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.607	0.205
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.379	0.599
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.4	0.72
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	1.373	0.307
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.227	0.702
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.019	0.982
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.56	0.545
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0	1
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0	1
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.677	0.00161

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of GPIHBP1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	16.7	-16.7	0.429
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	GPIHBP1
Name	glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1
Aliases	LOC338328; GPI-HBP1; endothelial cell LPL transporter; GPI anchored high density lipoprotein binding protein ......
Chromosomal Location	8q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GPIHBP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	GPIHBP1
Name	glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1
Aliases	LOC338328; GPI-HBP1; endothelial cell LPL transporter; GPI anchored high density lipoprotein binding protein ......
Chromosomal Location	8q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GPIHBP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GPIHBP1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	GPIHBP1
Name	glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1
Aliases	LOC338328; GPI-HBP1; endothelial cell LPL transporter; GPI anchored high density lipoprotein binding protein ......
Chromosomal Location	8q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GPIHBP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	GPIHBP1
Name	glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1
Aliases	LOC338328; GPI-HBP1; endothelial cell LPL transporter; GPI anchored high density lipoprotein binding protein ......
Chromosomal Location	8q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of GPIHBP1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	GPIHBP1
Name	glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1
Aliases	LOC338328; GPI-HBP1; endothelial cell LPL transporter; GPI anchored high density lipoprotein binding protein ......
Chromosomal Location	8q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between GPIHBP1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	GPIHBP1
Name	glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1
Aliases	LOC338328; GPI-HBP1; endothelial cell LPL transporter; GPI anchored high density lipoprotein binding protein ......
Chromosomal Location	8q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting GPIHBP1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse GPIHBP1